;

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Headlines > Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval

Headlines

Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval

Published by Global Banking and Finance Review

Posted on July 8, 2025

Featured image for article about Headlines

STOCKHOLM (Reuters) -Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants achieving 25% or more weight loss.

Novo Nordisk said in a statement it aimed to make the higher dose available throughout the European Union.

"This marks another significant milestone in the company’s goal to provide a broad portfolio of innovative and person-centric solutions to support people living with obesity," it said.

(Reporting by Anna Ringstrom. Editing by Essi Lehto and Mark Potter)

More from Headlines

Explore more articles in the Headlines category

FCAS fighter jet "very unlikely" after ministers' talks, source says

Campari's parent company settles tax dispute with 405 million euro payment

Universal offers to sell Downtown's Curve to win EU approval, source says

Auto sector divided as EU unveils plans to undo 2035 combustion engine ban

Italy's offshore wind push languishes, putting climate goals at risk

New Rome metro stations showcase ancient treasures after years of delays

New Czech government signals tough stance on migration, EU emissions rules

What's in the European Commission's proposals to reverse 2035 combustion engine ban?

Zaporizhzhia nuclear plant running on single power line, Russia says

No news on whereabouts or health of Iranian Nobel laureate Narges Mohammadi, supporters say

EU talks to fund Ukraine with Russian assets make progress, key decisions seen Thursday

Germany wraps up Patriot air defence mission in Poland

View All Headlines Posts